Gonorrhoea Resistance: England Cases Rise
- New data from the UK Health Security Agency (UKHSA) indicates a troubling increase in antibiotic-resistant gonorrhea infections in England.
- While total gonorrhea diagnoses saw a 16% drop—from 85,370 in 2023 to 71,802 in 2024—the UKHSA is raising alarms about the growing threat of drug-resistant strains.The decline was...
- Ceftriaxone, the primary treatment for gonorrhea, is facing increasing resistance.
England confronts a surge in antibiotic-resistant gonorrhea cases, even as overall diagnoses dip. The UK Health Security agency reports a troubling rise in drug-resistant strains, despite a 16% decrease in total gonorrhea cases during 2024. Ceftriaxone, the primary treatment, faces growing resistance, with travel-linked cases from the Asia-Pacific region contributing to the problem. The news is covered by News Directory 3.concurrently, a new vaccination programme targets at-risk groups by utilizing the meningococcal B vaccine, which has been shown to potentially reduce gonorrhea incidence. The health officials are urging for regular STI testing as part of intervention. Will thes measures halt the rise of the gonorrhea? Discover what’s next in this evolving health crisis.
Rise in Antibiotic-Resistant Gonorrhea Cases Sparks Concern in England
Updated June 04,2025
New data from the UK Health Security Agency (UKHSA) indicates a troubling increase in antibiotic-resistant gonorrhea infections in England. This comes despite an overall decrease in gonorrhea cases.
While total gonorrhea diagnoses saw a 16% drop—from 85,370 in 2023 to 71,802 in 2024—the UKHSA is raising alarms about the growing threat of drug-resistant strains.The decline was most notable among young people aged 15 to 24, with a 36% reduction in diagnoses.
Ceftriaxone, the primary treatment for gonorrhea, is facing increasing resistance. Although ceftriaxone resistance remains rare in the UK, it is more common in the Asia-Pacific region, with many UK cases linked to travel from that area. In the first five months of 2025, 14 cases of ceftriaxone-resistant gonorrhea were identified, exceeding the 13 cases reported in all of 2024. Six of this year’s cases showed resistance to both ceftriaxone and second-line treatments, making them extensively drug-resistant.
The UKHSA data also revealed that total new STI diagnoses decreased by 8.8%, from 399,947 in 2023 to 364,750 in 2024. Chlamydia cases fell by 13%,and first-episode genital warts cases dropped by 4.3%. though, early-stage syphilis diagnoses increased by 1.7%, contributing to an overall rise in syphilis cases. Genital herpes diagnoses also rose by 3.5%.
According to Dr. Hamish Mohammed, consultant epidemiologist at the UKHSA, STIs remain a significant public health concern. He urged individuals who have engaged in unprotected sex with new or casual partners to undergo annual STI and HIV testing, irrespective of symptoms.
STIs remain a significant threat to sexual well-being. Anyone who has had condomless sex with new or casual partners – either in the UK or abroad – should test for STIs and HIV at least annually, even without symptoms.
Dr Hamish Mohammed, consultant epidemiologist at the UKHSA
To combat the spread of gonorrhea, especially drug-resistant strains, england launched a gonorrhoea vaccination program in August. The program targets at-risk groups, such as gay and bisexual men with a history of multiple partners or bacterial STIs, offering the meningococcal B (4CMenB) vaccine. Studies suggest this vaccine may reduce gonorrhea incidence by up to 40%.
The gonorrhoea vaccination programme is a crucial step forward in providing protection.
Dr Amanda Doyle, national director for primary care, community, vaccination, and screening services at NHS England
What’s next
Health officials anticipate the gonorrhoea vaccination program will impact future diagnoses. Continued monitoring of antibiotic resistance and promotion of regular STI testing remain crucial in managing sexual health across England.